Core Viewpoint - Merit Medical (MMSI) shows potential for significant upside, with a mean price target of $104.27 indicating a 26.8% increase from its current price of $82.22 [1] Price Targets and Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $9.12, suggesting variability among analysts [2] - The lowest estimate is $90.00, indicating a 9.5% increase, while the highest estimate is $122.00, suggesting a potential surge of 48.4% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about MMSI's earnings prospects, as indicated by upward revisions in EPS estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with two estimates moving higher and no negative revisions [12] - MMSI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Masimo (MASI) has shown a 7.2% increase in stock price over the past four weeks, with a mean price target of $183.75 indicating a potential upside of 31.1% from the current price of $140.2 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $16.06, where the lowest estimate is $162.00 (15.6% increase) and the highest is $210.00 (49.8% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about MASI's earnings prospects, with a positive trend in earnings estimate revisions indicating potential upside [4][11] - Over the last 30 days, two earnings estimates have been revised higher, leading to a 0.3% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - MASI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the magnitude of MASI's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Corvus Pharmaceuticals (CRVS) has seen a significant price increase of 208.9% over the past four weeks, with a mean price target of $28.83 suggesting a further upside potential of 25.3% from the current trading price of $23.01 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $7.6, indicating variability among analysts; the lowest estimate is $20.00 (13.1% decline), while the highest is $42.00 (82.5% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about CRVS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3% over the past month, with one estimate increasing and no negative revisions [12] - CRVS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, their reliability has been questioned; empirical research indicates that they may mislead rather than guide investment decisions [3][7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Group 1 - Marex Group PLC (MRX) shares have increased by 1.2% over the past four weeks, closing at $39.15, with a mean price target of $50.29 indicating a potential upside of 28.5% [1] - The average price targets from analysts range from a low of $36.00 to a high of $61.00, with a standard deviation of $8.48, suggesting variability in estimates [2] - Analysts are optimistic about MRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for MRX has increased by 1.6% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - MRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of MRX's gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - SEI Investments (SEIC) shares have increased by 4.9% recently, closing at $85.99, with analysts suggesting a potential upside of 27.3% based on a mean price target of $109.5 [1] Price Targets - The average price target for SEIC ranges from a low of $102.00 to a high of $117.00, with a standard deviation of $8.66, indicating a potential increase of 18.6% to 36.1% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [8] Earnings Estimates - Analysts have shown increasing optimism about SEIC's earnings prospects, with a consensus indicating higher earnings estimates, which historically correlates with stock price movements [10] - The Zacks Consensus Estimate for the current year has risen by 1.2% over the past month, reflecting two upward revisions and one downward revision [11] - SEIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside [12] Analyst Behavior - Analysts often set price targets that may be overly optimistic due to business incentives, which can lead to inflated estimates [7] - While price targets are a common metric, relying solely on them for investment decisions may not be prudent, as they can mislead investors [6][9]

Core Viewpoint - Dutch Bros (BROS) has shown a recent price increase and analysts suggest significant upside potential based on price targets, with a mean target indicating a 29.1% increase from the current price [1]. Price Targets and Estimates - The mean price target for BROS is $77.61, derived from 18 short-term estimates with a standard deviation of $7.62, indicating variability among analysts [2]. - The lowest estimate is $63.00, suggesting a 4.8% increase, while the highest estimate is $95.00, indicating a potential surge of 58% [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price direction, which can be a starting point for further research [9]. Analyst Sentiment and Earnings Estimates - Analysts have shown growing optimism regarding BROS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has increased by 3.8% over the past month, with one estimate rising and no negative revisions [12]. - BROS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for upside [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates that they rarely predict actual stock price movements accurately [7]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]. - Investors are advised to treat price targets with skepticism and not rely solely on them for investment decisions [10].

Group 1: Stock Performance and Price Targets - Skyward Specialty Insurance (SKWD) closed at $48.62, with a 4.3% gain over the past four weeks, and a mean price target of $63.2 suggests a 30% upside potential [1] - The mean estimate includes 10 short-term price targets with a standard deviation of $9.08, indicating variability; the lowest estimate is $49.00 (0.8% increase), while the highest is $80.00 (64.5% increase) [2] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Group 2: Analyst Insights and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price upside; the Zacks Consensus Estimate for the current year has increased by 14% over the past month [11][12] - SKWD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While price targets may not be reliable for predicting exact gains, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Interactive Brokers Group, Inc. (IBKR) shows potential for significant upside, with a mean price target of $80.13 indicating a 27.3% increase from the current price of $62.94 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $72.00 to a high of $85.00, with a standard deviation of $4.58, suggesting a consensus among analysts [2] - The lowest estimate indicates a 14.4% increase, while the highest suggests a 35.1% upside [2] - A low standard deviation indicates greater agreement among analysts regarding price movement [2][9] Analyst Sentiment - Analysts are increasingly optimistic about IBKR's earnings prospects, as evidenced by upward revisions in EPS estimates, which correlate with potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 0.2% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - IBKR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set unbiased targets has been questioned [3][10] - Price targets should be approached with skepticism, as they can mislead investors [7][10]

Core Viewpoint - Vista Energy, S.A.B. de C.V. (VIST) shows potential for significant upside, with a mean price target of $69.8 indicating a 41.1% increase from its current price of $49.46 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $12.21, indicating variability among analysts [2] - The lowest estimate is $50.00, suggesting a 1.1% increase, while the highest estimate is $88.00, indicating a potential surge of 77.9% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about VIST's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 38.1% rise in the Zacks Consensus Estimate for the current year [12] - VIST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism, as they may not reliably indicate actual stock price movements [10]

Core Viewpoint - Ooma (OOMA) shows potential for significant upside, with a mean price target of $18.63 indicating a 56.8% increase from its current price of $11.88, supported by positive earnings estimate revisions and analyst agreement [1][11]. Price Targets and Analyst Estimates - The mean price target consists of four short-term estimates with a standard deviation of $0.95, suggesting a consensus among analysts. The lowest estimate is $18.00 (51.5% increase), while the highest is $20.00 (68.4% increase) [2][9]. - Analysts have shown strong agreement in revising earnings estimates higher, with four estimates moving up in the last 30 days and no negative revisions, leading to a 23.1% increase in the Zacks Consensus Estimate [12][11]. Analyst Behavior and Market Sentiment - There is skepticism regarding the reliability of price targets, as they often mislead investors. Analysts may set overly optimistic targets due to business incentives, which can inflate expectations [3][8]. - Despite the skepticism, a tight clustering of price targets indicates a high degree of agreement among analysts about the stock's price direction, which can serve as a starting point for further research [9][10]. Zacks Rank and Investment Potential - OOMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]. - While the consensus price target may not be a definitive indicator of potential gains, the implied direction of price movement appears to be a useful guide for investors [14].